original ) (raw )A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years
Veronique Bianco
Human Vaccines & Immunotherapeutics, 2012
View PDFchevron_right
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children
Veronique Bianco
Vaccine, 2011
View PDFchevron_right
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study
Veronique Bianco , Cecilia Montalban
BMC Infectious Diseases, 2013
View PDFchevron_right
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
Ghassan Dbaibo
Infection and Drug Resistance, 2014
View PDFchevron_right
Safety and Immunogenicity of Two Doses of Quadrivalent Meningococcal Conjugate Vaccine or One Dose of Meningococcal Group C Conjugate Vaccine, both Administered Concomitantly with Routine Immunization to 12- to 18-Month-Old Children
Himanshu Dubey
Canadian Journal of Infectious Diseases and Medical Microbiology, 2014
View PDFchevron_right
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
Sven Arne Silfverdal
International Journal of Infectious Diseases, 2012
View PDFchevron_right
Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age
Leonard Friedland , Carmen Baccarini , Yaela Baine
Journal of the Pediatric Infectious Diseases Society, 2014
View PDFchevron_right
A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial
Veronique Bianco
Vaccine, 2012
View PDFchevron_right
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
Shabir Madhi
The Pediatric Infectious Disease Journal, 2011
View PDFchevron_right
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study
Devayani Kolhe
Vaccine, 2018
View PDFchevron_right
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial
Devayani Kolhe
BMC infectious diseases, 2015
View PDFchevron_right
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine
Beatriz Quiambao
Human Vaccines & Immunotherapeutics
View PDFchevron_right
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine
Noel Macalalad , Mari Rose Aplasca-de Los Reyes
Human Vaccines & Immunotherapeutics, 2012
View PDFchevron_right
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age
Alejandra Valencia
Vaccine, 2010
View PDFchevron_right
Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
Veronique Bianco
Human Vaccines, 2011
View PDFchevron_right
Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
Otto Vanderkooi
Vaccine, 2012
View PDFchevron_right
Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
Veronique Bianco , Ghassan Dbaibo
Drugs & Aging, 2013
View PDFchevron_right
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants
Nan-chang Chiu
Vaccine, 2014
View PDFchevron_right
Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age
Stephen Lockhart
Vaccine, 2001
View PDFchevron_right
Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review
Ghassan Dbaibo
Expert Opinion on Biological Therapy, 2013
View PDFchevron_right
Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT, Nimenrix™): A review of its Immunogenicity, Safety, Co-Administration, and Antibody Persistence
Aia Assaf Casals
Human vaccines & immunotherapeutics, 2016
View PDFchevron_right
Five-Year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W, and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial
Devayani Kolhe
The Pediatric infectious disease journal, 2015
View PDFchevron_right
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial
subhash kapre
Vaccine, 2012
View PDFchevron_right
Vaccines for the prevention of meningococcal disease in children
M. Soriano-gabarró
Seminars in Pediatric Infectious Diseases, 2002
View PDFchevron_right
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
Marie-Laure Kürzinger
Infectious Diseases and Therapy
View PDFchevron_right